Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

18:01
09/21/18
09/21
18:01
09/21/18
18:01

Johnson & Johnson's Janssen discloses phase 3 study results of Esketamine

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from a Phase 3 clinical study of the investigational product esketamine nasal spray in patients with treatment-resistant depression. Janssen researchers presented these results at the Ninth Biennial Conference of the International Society for Affective Disorders (ISAD) and the Houston Mood Disorders Conference, taking place September 20-22, 2018 in Houston, TX. This clinical trial was a randomized, double-blind study of two fixed doses of esketamine, 56 mg and 84 mg. The study did not demonstrate statistical significance for the primary endpoint, change in a depression severity rating scale score from baseline to four weeks, for esketamine 84 mg plus oral antidepressant compared to oral antidepressant plus placebo. Therefore, based on the prespecified analysis plan, the esketamine 56 mg plus oral antidepressant group could not be formally evaluated in this study. Importantly, results of analyses of the primary endpoint and key secondary endpoints numerically favored both esketamine plus oral antidepressant treatment groups over the oral antidepressant plus placebo group.

  • 16

    Oct

  • 28

    Oct

JNJ Johnson & Johnson
$142.85

0.85 (0.60%)

09/14/18
WELS
09/14/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson price target raised to $160 from $150 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Johnson & Johnson to $160 after the company hosted an investor call to provide an update on its Pharmaceuticals business. The analyst heard no strategic change to the business saying J&J maintains focus on its six key therapeutic areas and remains agnostic to the source of innovation. While the company did not provide 2019 guidance, management's tone came across as confident in the business outlook, Biegelsen tells investors in a research note. He keeps an Outperform rating on Johnson & Johnson.
08/27/18
MSCO
08/27/18
NO CHANGE
MSCO
Equal Weight
Portola may be up 'somewhat' on Xarelto trial failure, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted the failure of Johnson & Johnson's (JNJ)MARINER study, which was examining Xarelto, a competing anticogulant to Portola's (PTLA) BevyxXa. MARINER's failure to demonstrate a statistically significant result of reducing symptomatic VTE or death due to VTE is expected by Harrison to send Portola shares up "somewhat," but he believes most investors had already lowered their expectations for the BevyxXa franchise after the Q2 report, making the impact modest. He maintains an Equal Weight rating on Portola shares, which are up 3% to $29 per share in early trading.
08/27/18
WBLR
08/27/18
NO CHANGE
WBLR
Outperform
Mariner failure removes potential Portola competition, says William Blair
William Blair analyst Matt Phipps says that while the failure of Johnson & Johnson's (JNJ) Mariner trial removes potential competition Portola Pharmaceuticals' (PTLA) Bevyxxa, which is positive, "significant work" is still needed to gain adoption of Bevyxxa in the United States. As such, the Mariner results do not significantly alter the near-term headwinds for Bevyxxa, Phipps tells investors in a research note. The analyst believes getting beyond the Mariner presentation allows investors to focus on the opportunity for Andexxa, which he still thinks is "significant." He points out that Portola remains on track to file the prior approval supplement for the second-generation manufacturing process of Andexxa in the coming days, which would provide sufficient supply for 1,000 hospitals in the United States and expansion into Europe. Phipps keeps an Outperform rating on Portola Pharmaceuticals, which is up 5% to $29.60 in premarket trading.
08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.

TODAY'S FREE FLY STORIES

SPRO

Spero Therapeutics

$9.83

0.23 (2.40%)

06:18
10/16/18
10/16
06:18
10/16/18
06:18
Downgrade
Spero Therapeutics rating change  »

Spero Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RACE

Ferrari

$115.06

-1.34 (-1.15%)

, PYPL

PayPal

$77.22

-1.8 (-2.28%)

06:17
10/16/18
10/16
06:17
10/16/18
06:17
Recommendations
Ferrari, PayPal, ADP, NetApp analyst commentary  »

Ferrari, PayPal added to…

RACE

Ferrari

$115.06

-1.34 (-1.15%)

PYPL

PayPal

$77.22

-1.8 (-2.28%)

ADP

ADP

$140.27

-0.44 (-0.31%)

NTAP

NetApp

$75.35

-1.61 (-2.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 31

    Oct

  • 13

    Nov

  • 26

    Nov

MBWM

Mercantile Bank

$32.28

0.59 (1.86%)

06:17
10/16/18
10/16
06:17
10/16/18
06:17
Hot Stocks
Mercantile Bank announces 75c special cash dividend »

Mercantile Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

HF

HFF Inc.

$36.99

0.6 (1.65%)

06:17
10/16/18
10/16
06:17
10/16/18
06:17
Hot Stocks
HFF sells Sheraton Denver Downtown Hotel »

Holliday Fenoglio Fowler…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$73.00

0.51 (0.70%)

, SHLD

Sears

$0.31

-0.0901 (-22.52%)

06:16
10/16/18
10/16
06:16
10/16/18
06:16
Recommendations
Best Buy, Sears analyst commentary  »

Best Buy to be major…

BBY

Best Buy

$73.00

0.51 (0.70%)

SHLD

Sears

$0.31

-0.0901 (-22.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$0.00

(0.00%)

, BMWYY

BMW

$0.00

(0.00%)

06:16
10/16/18
10/16
06:16
10/16/18
06:16
Periodicals
Daimler, BMW offer concessions to ease EU antitrust concerns, Reuters reports »

Germany luxury automakers…

DDAIF

Daimler AG

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPR

Tapestry

$43.09

-0.72 (-1.64%)

06:16
10/16/18
10/16
06:16
10/16/18
06:16
Upgrade
Tapestry rating change  »

Tapestry upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

SYMC

Symantec

$19.78

0.19 (0.97%)

06:15
10/16/18
10/16
06:15
10/16/18
06:15
Upgrade
Symantec rating change  »

Symantec upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Dec

BLK

BlackRock

$427.40

-0.18 (-0.04%)

06:14
10/16/18
10/16
06:14
10/16/18
06:14
Hot Stocks
BlackRock CEO: Q3 results highlight resilience of our differentiated platform »

Laurence Fink, Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

TWLO

Twilio

$76.26

1.27 (1.69%)

, SEND

SendGrid

$30.94

0.04 (0.13%)

06:14
10/16/18
10/16
06:14
10/16/18
06:14
Recommendations
Twilio, SendGrid analyst commentary  »

Twilio should be bought…

TWLO

Twilio

$76.26

1.27 (1.69%)

SEND

SendGrid

$30.94

0.04 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

MBWM

Mercantile Bank

$32.28

0.59 (1.86%)

06:13
10/16/18
10/16
06:13
10/16/18
06:13
Earnings
Mercantile Bank reports Q3 EPS 61c, consensus 61c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

BLK

BlackRock

$427.40

-0.18 (-0.04%)

06:12
10/16/18
10/16
06:12
10/16/18
06:12
Hot Stocks
BlackRock reports $11B of quarterly long-term net inflows in Q3 »

Led by iShares, active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

BLK

BlackRock

$427.40

-0.18 (-0.04%)

06:11
10/16/18
10/16
06:11
10/16/18
06:11
Hot Stocks
BlackRock reports Q3 AUM $6.4T, up 8% y/y »

Including $28B of net AUM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

ADBE

Adobe

$238.05

-10.84 (-4.36%)

06:11
10/16/18
10/16
06:11
10/16/18
06:11
Recommendations
Adobe analyst commentary  »

Adobe remains a top pick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$133.75

-0.03 (-0.02%)

, SNY

Sanofi

$43.45

0.56 (1.31%)

06:10
10/16/18
10/16
06:10
10/16/18
06:10
Periodicals
Pharma pushes back against required listing of drug prices in TV ads, WSJ says »

The pharmaceutical…

JNJ

Johnson & Johnson

$133.75

-0.03 (-0.02%)

SNY

Sanofi

$43.45

0.56 (1.31%)

RHHBY

Roche

$0.00

(0.00%)

AZN

AstraZeneca

$37.46

0.31 (0.83%)

PFE

Pfizer

$43.11

-0.67 (-1.53%)

LLY

Eli Lilly

$110.69

0.2 (0.18%)

MRK

Merck

$69.46

-0.31 (-0.44%)

GSK

GlaxoSmithKline

$38.87

0.56 (1.46%)

NVS

Novartis

$83.14

0.37 (0.45%)

BMY

Bristol-Myers

$57.59

0.09 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 24

    Dec

  • 11

    Jan

  • 28

    Jan

  • 16

    Feb

  • 22

    Mar

  • 28

    Apr

AMZN

Amazon.com

$1,760.99

-27.64 (-1.55%)

06:10
10/16/18
10/16
06:10
10/16/18
06:10
Periodicals
Amazon's announcement of HQ2 'imminent,' Recode reports »

Amazon's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

UTHR

United Therapeutics

$123.41

0.26 (0.21%)

, MNKD

MannKind

$1.66

0.06 (3.75%)

06:10
10/16/18
10/16
06:10
10/16/18
06:10
Hot Stocks
United Therapeutics, MannKind announce closing of license agreement »

United Therapeutics…

UTHR

United Therapeutics

$123.41

0.26 (0.21%)

MNKD

MannKind

$1.66

0.06 (3.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$427.40

-0.18 (-0.04%)

06:09
10/16/18
10/16
06:09
10/16/18
06:09
Earnings
BlackRock reports Q3 adjusted EPS $7.52, consensus $6.84 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

JBHT

J.B. Hunt

$111.78

2.52 (2.31%)

06:08
10/16/18
10/16
06:08
10/16/18
06:08
Hot Stocks
J.B. Hunt CFO says Oct peak season freight should be 'very normal', Dec 'strong' »

In its conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

LN

Line Corp.

$35.10

-0.81 (-2.26%)

06:07
10/16/18
10/16
06:07
10/16/18
06:07
Upgrade
Line Corp. rating change  »

Line Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$11.42

0.03 (0.26%)

06:06
10/16/18
10/16
06:06
10/16/18
06:06
Upgrade
Noodles & Company rating change  »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$0.00

(0.00%)

, AUDVF

Audi AG

$0.00

(0.00%)

06:06
10/16/18
10/16
06:06
10/16/18
06:06
Hot Stocks
Volkswagen reports negative special items from Audi administrative order »

Volkswagen (VLKAY)…

VLKAY

Volkswagen

$0.00

(0.00%)

AUDVF

Audi AG

$0.00

(0.00%)

POAHY

Porsche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$121.06

-1.61 (-1.31%)

06:06
10/16/18
10/16
06:06
10/16/18
06:06
Recommendations
Wayfair analyst commentary  »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 03

    Mar

GOV

Government Properties

06:04
10/16/18
10/16
06:04
10/16/18
06:04
Upgrade
Government Properties rating change  »

Government Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

SNN

Smith & Nephew

$34.14

-0.42 (-1.22%)

06:04
10/16/18
10/16
06:04
10/16/18
06:04
Downgrade
Smith & Nephew rating change  »

Smith & Nephew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.